XPH 📈 SPDR S&P Pharmaceuticals - Overview

Exchange: NYSE ARCA • Country: USA • Currency: USD • Type: Etf • ISIN: US78464A7220 • Health

XPH: Pharmaceuticals, Prescription, Medicines, Vaccines, Biotechnology, Therapies

The SPDR S&P Pharmaceuticals ETF (XPH) is an exchange-traded fund (ETF) designed to track the performance of the S&P Pharmaceuticals Select Industry Index. To achieve this, the fund uses a sampling strategy, which means it selects a representative portion of the securities in the index to invest in.

The ETF typically invests at least 80% of its total assets in the securities that make up the index, which is a subset of the S&P Total Market Index (S&P TMI). This index represents the pharmaceuticals segment of the broader market, providing investors with targeted exposure to this specific industry.

By investing in the SPDR S&P Pharmaceuticals ETF, investors can gain access to a diversified portfolio of pharmaceutical companies, which can help spread risk and potentially increase returns. The fund's focus on the pharmaceuticals industry also allows investors to tap into the growth potential of this sector, which is driven by advances in medical research, technology, and healthcare demand.

The SPDR S&P Pharmaceuticals ETF is listed on the NYSE Arca exchange under the ticker symbol XPH, and its website can be found at http://www.spdrs.com. As a US-domiciled fund, it is subject to the regulatory framework of the United States.

Additional Sources for XPH ETF

XPH ETF Overview

Market Cap in USD 158m
Category Health
TER 0.35%
IPO / Inception 2006-06-19

XPH ETF Ratings

Growth 5y 9.35%
Fundamental -
Dividend 53.0%
Rel. Performance Sector -0.56
Analysts -
Fair Price Momentum 44.95 USD
Fair Price DCF -

XPH Dividends

Dividend Yield 12m 1.53%
Yield on Cost 5y 1.80%
Annual Growth 5y 12.87%
Payout Consistency 89.42%

XPH Growth Ratios

Growth Correlation 3m 71.4%
Growth Correlation 12m 58.8%
Growth Correlation 5y -21.8%
CAGR 5y 3.38%
CAGR/Mean DD 5y 0.20
Sharpe Ratio 12m 0.99
Alpha -6.58
Beta 0.80
Volatility 18.13%
Current Volume 12.9k
Average Volume 20d 72k
What is the price of XPH stocks?
As of December 04, 2024, the stock is trading at USD 45.70 with a total of 12,900 shares traded.
Over the past week, the price has changed by +0.72%, over one month by +0.63%, over three months by +5.79% and over the past year by +22.87%.
Is SPDR S&P Pharmaceuticals a good stock to buy?
Neither. Based on ValueRay Analyses, SPDR S&P Pharmaceuticals is currently (December 2024) neither a good nor a bad stock to buy. It has a ValueRay Growth Rating of 9.35 and therefor a technical neutral rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of XPH as of December 2024 is 44.95. This means that XPH is currently overvalued and has a potential downside of -1.64%.
Is XPH a buy, sell or hold?
SPDR S&P Pharmaceuticals has no consensus analysts rating.
What are the forecast for XPH stock price target?
According to ValueRays Forecast Model, XPH SPDR S&P Pharmaceuticals will be worth about 49.7 in December 2025. The stock is currently trading at 45.70. This means that the stock has a potential upside of +8.69%.
Issuer Forecast Upside
Wallstreet Target Price - -
Analysts Target Price - -
ValueRay Target Price 49.7 8.7%